COMMUNIQUÉS West-GlobeNewswire

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 22:30

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43 rd Annual J.P. Morgan [...]

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

23/12/2024 - 22:49

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“ Neuphoria ” or the “ Company ”) is pleased to announce that its previously announced scheme of arrangement in relation [...]

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

23/12/2024 - 17:30

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular degeneration Trial planned to enroll 110 patients in the US, Europe, and Israel [...]

Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis

23/12/2024 - 18:58

HALIFAX, Nova Scotia and SPRING, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Scientists at Dalhousie University in Halifax, and Io Therapeutics, Inc. in Spring Texas, announced today collaborative publication of data from [...]

NewGen Progresses Reverse Merger Plans with Engagement of Legal Teams and Updated Timeline

23/12/2024 - 13:30

BANGKOK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today announced that both parties involved in the previously announced reverse merger with European Wellness [...]

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

23/12/2024 - 13:30

Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and [...]

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

23/12/2024 - 13:30

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT- [...]

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

23/12/2024 - 13:30

Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today [...]

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 13:30

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

23/12/2024 - 13:30

Cash Runway Extended Beyond Planned NDA Submission of CTx-1301 KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed [...]

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

23/12/2024 - 13:30

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application ( [...]

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23/12/2024 - 13:30

Company to host a webcast t oday at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company [...]

Aveanna to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

23/12/2024 - 13:30

ATLANTA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the 43 rd Annual J.P. Morgan Healthcare Conference in San [...]

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

23/12/2024 - 13:45

Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations and development [...]

FibroBiologics Announces $25 Million Financing

23/12/2024 - 13:55

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]

Psyence Biomed Announces $2.0 Million Private Placement

23/12/2024 - 14:00

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company“) today announced that it has entered into definitive agreements for the purchase and sale of an [...]

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

23/12/2024 - 14:00

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and [...]

Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia

23/12/2024 - 14:00

Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA [...]

Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs

23/12/2024 - 14:00

Patent for methods of use of topical DNase enzymes in the eye covers L304, Neutrolis’ proprietary therapy in development for the treatment of moderate to severe dry eye disease CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE [...]